A study demonstrated that among individuals hospitalized with COVID-19 infection, subjects having autoimmune disorders did not have a raised risk of a composite outcome of ICU admission, intubation, or mortality.

A retrospective cohort study was carried out in New York to analyze the impact of autoimmune disease on the clinically relevant composite outcomes such as ICU admission, intubation, or mortality from COVID-19 in a large cohort of hospitalized patients. The study enrolled 186 hospitalized autoimmune patients having COVID-19.

The cohort incorporated 62 participants having an autoimmune disease and 124 gender- and age-matched controls. The primary endpoint was a composite of noxious events comprising of ICU admission, intubation, and mortality. The secondary endpoint was determining the time to in-hospital mortality. The baseline demographics, medications, vital signs, comorbidities, and laboratory values were gathered.

To examine the link between autoimmune disease and clinical outcomes, the Cox proportional hazards regression and the conditional logistic regression were utilized. Participants having autoimmune conditions were more likely to have at least one comorbidity, take chronic immunosuppressive agents, and have solid organ transplantation. No substantial differences were noted in ICU admission, intubation, and mortality, as shown in the following table:

On multivariable analysis, subjects having autoimmune conditions were not at an elevated risk for ICU admission, intubation, or mortality (_adjOR 0.79). On Cox regression, the autoimmune condition was not linked with in-hospital death (_adjHR 0.73), as shown in the following figure:

Further investigation is required to improve the treatment of individuals suffering from autoimmune disorders in the context of COVID-19, specifically with regard to utilizing additional immunosuppression therapy in the inpatient setting.